High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT

J. W. Sweetenham, G. Taghipour, D. Milligan, A. K. Blystad, D. Caballero, A. Fassas, A. H. Goldstone

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

The purpose of this study was to investigate the results of high-dose therapy and autologous stem cell transplantation in adult patients with Hodgkin's disease first relapse after chemotherapy, to determine the overall and progression-free survival, identify prognostic factors for outcome, and to define the role of conventional dose salvage therapy given prior to the high dose regimen. A retrospective analysis of 139 adult patients reported to the lymphoma registry of the European Group for Blood and Marrow Transplantation (EBMT) between February 1984 and July 1995 is considered. Data on all patients were reviewed and prognostic factors determined in univariate analysis. The actuarial 5-year overall survival (OS) and progression-free survival (PFS) for the entire group of 139 patients were 49.4 and 44.7%, respectively. In univariate analysis for OS, disease bulk at the time of high-dose therapy, second-line regimen, initial remission duration and status at transplant had no predictive value. Status at transplant was predictive for OS when patients in second complete remission (CR) were analysed separately from those in chemosensitive relapse. Similar trends were observed for PFS. We concluded that high-dose therapy and autologous stem cell transplantation is an effective strategy for patients with Hodgkin's disease in first relapse after chemotherapy. These results suggest that it should be used regardless of initial remission duration. The role of conventional-dose salvage given prior to high-dose therapy is unclear, since disease status, disease bulk at the time of transplantation, and the second-line regimen had no significant effect on outcome. However, in view of the low patient numbers, no firm conclusion is possible, and this issue requires prospective assessment.

Original languageEnglish (US)
Pages (from-to)745-752
Number of pages8
JournalBone Marrow Transplantation
Volume20
Issue number9
DOIs
StatePublished - Nov 1 1997
Externally publishedYes

Fingerprint

Blood Group Antigens
Hodgkin Disease
Stem Cells
Transplantation
Bone Marrow
Recurrence
Drug Therapy
Disease-Free Survival
Stem Cell Transplantation
Therapeutics
Transplants
Salvage Therapy
Survival
Survival Analysis
Registries
Lymphoma

Keywords

  • ASCT
  • First relapse
  • High-dose therapy
  • Hodgkin's disease

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy : Results from the EBMT. / Sweetenham, J. W.; Taghipour, G.; Milligan, D.; Blystad, A. K.; Caballero, D.; Fassas, A.; Goldstone, A. H.

In: Bone Marrow Transplantation, Vol. 20, No. 9, 01.11.1997, p. 745-752.

Research output: Contribution to journalArticle

Sweetenham, J. W. ; Taghipour, G. ; Milligan, D. ; Blystad, A. K. ; Caballero, D. ; Fassas, A. ; Goldstone, A. H. / High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy : Results from the EBMT. In: Bone Marrow Transplantation. 1997 ; Vol. 20, No. 9. pp. 745-752.
@article{f46df859d0e84f468b476ba99c869f40,
title = "High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: Results from the EBMT",
abstract = "The purpose of this study was to investigate the results of high-dose therapy and autologous stem cell transplantation in adult patients with Hodgkin's disease first relapse after chemotherapy, to determine the overall and progression-free survival, identify prognostic factors for outcome, and to define the role of conventional dose salvage therapy given prior to the high dose regimen. A retrospective analysis of 139 adult patients reported to the lymphoma registry of the European Group for Blood and Marrow Transplantation (EBMT) between February 1984 and July 1995 is considered. Data on all patients were reviewed and prognostic factors determined in univariate analysis. The actuarial 5-year overall survival (OS) and progression-free survival (PFS) for the entire group of 139 patients were 49.4 and 44.7{\%}, respectively. In univariate analysis for OS, disease bulk at the time of high-dose therapy, second-line regimen, initial remission duration and status at transplant had no predictive value. Status at transplant was predictive for OS when patients in second complete remission (CR) were analysed separately from those in chemosensitive relapse. Similar trends were observed for PFS. We concluded that high-dose therapy and autologous stem cell transplantation is an effective strategy for patients with Hodgkin's disease in first relapse after chemotherapy. These results suggest that it should be used regardless of initial remission duration. The role of conventional-dose salvage given prior to high-dose therapy is unclear, since disease status, disease bulk at the time of transplantation, and the second-line regimen had no significant effect on outcome. However, in view of the low patient numbers, no firm conclusion is possible, and this issue requires prospective assessment.",
keywords = "ASCT, First relapse, High-dose therapy, Hodgkin's disease",
author = "Sweetenham, {J. W.} and G. Taghipour and D. Milligan and Blystad, {A. K.} and D. Caballero and A. Fassas and Goldstone, {A. H.}",
year = "1997",
month = "11",
day = "1",
doi = "10.1038/sj.bmt.1700963",
language = "English (US)",
volume = "20",
pages = "745--752",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy

T2 - Results from the EBMT

AU - Sweetenham, J. W.

AU - Taghipour, G.

AU - Milligan, D.

AU - Blystad, A. K.

AU - Caballero, D.

AU - Fassas, A.

AU - Goldstone, A. H.

PY - 1997/11/1

Y1 - 1997/11/1

N2 - The purpose of this study was to investigate the results of high-dose therapy and autologous stem cell transplantation in adult patients with Hodgkin's disease first relapse after chemotherapy, to determine the overall and progression-free survival, identify prognostic factors for outcome, and to define the role of conventional dose salvage therapy given prior to the high dose regimen. A retrospective analysis of 139 adult patients reported to the lymphoma registry of the European Group for Blood and Marrow Transplantation (EBMT) between February 1984 and July 1995 is considered. Data on all patients were reviewed and prognostic factors determined in univariate analysis. The actuarial 5-year overall survival (OS) and progression-free survival (PFS) for the entire group of 139 patients were 49.4 and 44.7%, respectively. In univariate analysis for OS, disease bulk at the time of high-dose therapy, second-line regimen, initial remission duration and status at transplant had no predictive value. Status at transplant was predictive for OS when patients in second complete remission (CR) were analysed separately from those in chemosensitive relapse. Similar trends were observed for PFS. We concluded that high-dose therapy and autologous stem cell transplantation is an effective strategy for patients with Hodgkin's disease in first relapse after chemotherapy. These results suggest that it should be used regardless of initial remission duration. The role of conventional-dose salvage given prior to high-dose therapy is unclear, since disease status, disease bulk at the time of transplantation, and the second-line regimen had no significant effect on outcome. However, in view of the low patient numbers, no firm conclusion is possible, and this issue requires prospective assessment.

AB - The purpose of this study was to investigate the results of high-dose therapy and autologous stem cell transplantation in adult patients with Hodgkin's disease first relapse after chemotherapy, to determine the overall and progression-free survival, identify prognostic factors for outcome, and to define the role of conventional dose salvage therapy given prior to the high dose regimen. A retrospective analysis of 139 adult patients reported to the lymphoma registry of the European Group for Blood and Marrow Transplantation (EBMT) between February 1984 and July 1995 is considered. Data on all patients were reviewed and prognostic factors determined in univariate analysis. The actuarial 5-year overall survival (OS) and progression-free survival (PFS) for the entire group of 139 patients were 49.4 and 44.7%, respectively. In univariate analysis for OS, disease bulk at the time of high-dose therapy, second-line regimen, initial remission duration and status at transplant had no predictive value. Status at transplant was predictive for OS when patients in second complete remission (CR) were analysed separately from those in chemosensitive relapse. Similar trends were observed for PFS. We concluded that high-dose therapy and autologous stem cell transplantation is an effective strategy for patients with Hodgkin's disease in first relapse after chemotherapy. These results suggest that it should be used regardless of initial remission duration. The role of conventional-dose salvage given prior to high-dose therapy is unclear, since disease status, disease bulk at the time of transplantation, and the second-line regimen had no significant effect on outcome. However, in view of the low patient numbers, no firm conclusion is possible, and this issue requires prospective assessment.

KW - ASCT

KW - First relapse

KW - High-dose therapy

KW - Hodgkin's disease

UR - http://www.scopus.com/inward/record.url?scp=0030710532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030710532&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1700963

DO - 10.1038/sj.bmt.1700963

M3 - Article

C2 - 9384476

AN - SCOPUS:0030710532

VL - 20

SP - 745

EP - 752

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -